Journal of Cancer Science and Research
Open Access

Department of Surgical Oncology, Max Super Speciality Hospital, Shalimar Bagh, New Delhi 110088, India

Publications

• Research Article   
  Improved survival with DOF regimen for the treatment of metastatic gastric adenocarcinoma
  Author(s): Pratik P Patil*, Ranga Rao Rangaraju, Waseem Abbas, Rudra Prasad Acharya and Archit Pandit
  
  BACKGROUND: Patients with metastatic gastric adenocarcinoma have a relatively poor prognosis with a median survival of 6 months. The three-drug regimen of docetaxel, oxaliplatin and fluorouracil (DOF) has been shown to improve survival compared to the two-drug regimen of docetaxel and oxaliplatin with similar toxicity. However, there is no published Indian experience with this regimen. AIM: The aim of this study was to evaluate the efficacy of DOF regimen in Indian patients. MATERIAL AND METHODS: All patients with metastatic gastric cancer who were treated with DOF regimen at our tertiary care centre in North India from 2014 to 2018 were retrospectively reviewed. 15 patients received DOF regimen as docetaxel 60 mg/m2 and oxaliplatin 85 mg/m2 on Day 1, and continuous infusion 5-FU 750 mg/m2 over 48 hours with pegylated-granulocyte c.. View More»
  DOI: 10.35248/2576-1447.23.8.532

  Abstract HTML PDF